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Abstract
Background: The principal biomarker of neurodegeneration in multiple sclerosis (MS) is believed to be brain
volume, which is associated with cognitive functions and retinal nerve fibre layer (RNFL). A cross-sectional and
longitudinal assessment of the relationship between RNFL, cognitive functions and brain volume.
Methods: At baseline, relapsing patients and healthy controls underwent 1.5 T MRI to estimate the normalized
volume of brain (NBV), grey (NGV), white (NWV) and peripheral grey (pNGV) matter. Cognitive functions were
evaluated by BICAMS, RNFL by Spectral-Domain OCT. Patients were re-evaluated after 12 months.
Results: Cognitive functions, brain volume, and RNFL differed between the group of 66 patients and that of 16
healthy controls. In the MS group, at baseline, an association was found between: p-NGV and symbol-digit (SDMT)
(p = 0.022); temporal-RNFL and NBV (p = 0.007), NWV (p = 0.012), NGV (p = 0.048), and p-NGV (p = 0.021); papillo-
macular bundle-RNFL and NBV (p = 0.013), NWV (p = 0.02), NGV (p = 0.049), and p-NGV (p = 0.032). Over the
observational period, we found a reduction of brain volume (p < 0.001), average-RNFL (p = 0.001), temporal-RNFL
(p = 0.006), and papillo-macular bundle-RNFL (p = 0.009). No association was found between OCT, MRI, and
cognitive changes.
Conclusions: Brain volume, cognitive functions, and RNFL are continuous measures of different neurodegenerative
aspects. BICAMS and OCT have low costs and can be easily used in clinical practice to monitor neurodegeneration.
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Background
Multiple Sclerosis (MS) is a chronic disease involving
the central nervous system. The clinical course is
generally relapsing at onset, and later progressive [1].
Both the inflammatory and neurodegenerative compo-
nent is present from the early stages [1]. While the first
aspect has been well documented and is monitored in
clinical practice using conventional magnetic resonance
imaging (MRI), the study of neurodegeneration is more
difficult [2]. At present, an important biomarker of the
neurodegenerative aspect in MS is the evaluation of
brain volume by non-conventional techniques of MRI
[3]. Indeed, the loss of brain volume appears to be
related to the progression of the disease and the per-
manent accumulation of disability [3, 4]. One of the
most important symptoms related to brain atrophy is
the deficit of cognitive functions [5]. This is associated
with several MRI markers, in particular grey matter
pathology, both in terms of focal lesions and volume loss
[5]. Cognitive impairment, which has variable severity
and has been identified at all stages of the disease and
clinical courses, affects between 40 and 70% of MS pa-
tients [6]. It appears to be associated with age, disease
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duration and disability [7]. Many diagnostic tools are
able to explore cognitive functions in MS patients [8],
although the majority of these are time consuming and
require qualified personnel [8]. However, a recently
developed neuropsychological assessment named “Brief
International Cognitive Assessment for Multiple Sclerosis”
(BICAMS) can be administered by non-specifically trained
healthcare staff in around 15 min [8].
In the last decades, optic coherence tomography
(OCT), a new instrument for evaluating the neurodegen-
erative aspect of MS, has been widely studied [9, 10].
OCT is able to evaluate the thickness of the retinal
nerve fibre layer (RNFL), a defined marker of axonal
loss. RNFL measurement could differentiate MS patients
from healthy subjects, and it is clearly related to brain
atrophy, disease duration, and disability [10–14]. The
most involved RNFL region is the temporal quadrant
[15]. The great majority of studies exploring RNFL in
MS patients have been performed using a ‘time-domain’
OCT (considered the ‘old’ OCT model), which produces
less accurate images than the ‘spectral domain’ OCT
(SD-OCT), especially in longitudinal studies [16–19].
BICAMS and OCT share three important qualities for
MS assessment in a clinical setting: brevity, ease of use,
and low cost.
The present study entails a cross-sectional and longi-
tudinal assessment of the use of SD-OCT and BICAMS
in the evaluation of the neurodegenerative aspects of
MS. These procedures are compared with MRI brain at-
rophy measurements, which are currently considered
the gold standard among neurodegenerative markers in
MS patients.
Methods
MS-relapsing patients consecutively referred to the MS
Centre of the University of Cagliari/Binaghi Hospital
from March to July 2015 were prospectively included in
the study. A group of healthy controls working in the
Binaghi hospital was also recruited over the same time
period. All the subjects signed an informed consent. The
inclusion criteria for MS patients were: 18-65 years of
age; relapsing remitting course; no relapses and/or ste-
roids intake in the 30 days before enrolment and follow-
up evaluation. All patients started a disease-modifying
drug (DMD) prior to enrolment. Psychoactive drugs or
substances that might interfere with neuropsychological
performance were forbidden for both patients and
healthy controls.
The ethics committee of the University of Cagliari
approved the study.
At baseline, after written informed consent was given,
all the subjects underwent neuropsychological assess-
ment, brain MRI, and OCT. These three evaluations
were carried out within a maximum period of three
months. The evaluations were repeated for a group of
MS patients after 12 months ±3. The changes from
baseline and follow-up (difference between follow-up
and baseline) were calculated for all of the collected
MRI, OCT and BICAMS parameters collected.
Gender and age were collected for the whole cohort.
In the MS group, the following clinical data were also
recorded from medical records by a neurologist with ex-
pertise in MS: age at onset; clinical course; expanded
disability status scale score (EDSS) at baseline; all DMD
from six months before baseline until the end of the
study; presence of relapses and steroid therapy in the
30 days before baseline and before the follow-up evalu-
ation; and optic neuritis in the clinical history with indi-
cation of the affected eye. Eyes affected by previous
optic neuritis were excluded from the statistical analysis.
Neuropsychological evaluation
An expert neuropsychologist (G.F.) performed the
neuropsychological evaluation in a quiet room using the
BICAMS. This assessment was recently developed by an
expert consensus group and included: the Symbol Digit
Modality Test (SDMT) to evaluate processing speed (or
working memory); the California Verbal Learning Test II
(CVLT-II) to evaluate verbal learning and memory; and
the Brief Visual Memory Test Revised (BVMT-R) to
evaluate visual learning and memory [8, 20]. All tests
were considered normal or altered according to the au-
thors’ definition (T score equal or inferior to 35). T score
estimations were made using available normative values,
with corrections for age, gender and education among
the Italian population [20]. Patients were categorized as
either cognitive impaired (at least one test altered) or
cognitive preserved (no tests altered).
The neuropsychologist was blinded to clinical and
radiological findings.
Brain MR acquisition
Brain MRI acquisition and analysis was performed at the
Radiology Unit of Binaghi Hospital, Cagliari, Italy. The
operator was blinded to the clinical and neuropsycho-
logical status of the subjects. The acquisition of brain
MRIs was obtained in a single session, using a Siemens
Magneton Avanto Scan at 1.5 T. A sagittal survey image
was used to identify the anterior and posterior commis-
sures. A dual-echo, turbo spin-echo sequence (repetition
time/echo time 1/echo time 2 5 2075/30/90 milliseconds,
256 X 256 matrix, 1 signal average, 250 mm field of view,
50 contiguous 3 mm slices) yielding proton density–
weighted and T2-weighted images were acquired in the
transverse plane parallel to the line connecting the
anterior and posterior commissures. Transverse T1-
weighted (T1W) images (repetition time 35 millisec-
onds; echo time 10 milliseconds; 256 X 256 matrix; 1
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signal average; 2,503,250 mm field of view) were ac-
quired, yielding images of 176 contiguous 1 mm-thick
slices, oriented to match the proton density of the
T2-weighted image.
Brain parenchyma volumes were measured on T1W
gradient echo images by using the cross-sectional ver-
sion of the SIENA (structural image evaluation using
normalization of atrophy) software, named SIENAX
(part of FSL 4.0: http://www.fmrib.ox.ac.uk/fsl/), a previ-
ously described method to estimate global brain volume
normalized for head size [21]. MRI analysis allowed for
Normalized Brain Volume (NBV), Normalized Grey
Matter Volume (NGV), peripheral NGV (p-NGV), and
Normalized White Matter Volume (NWV) to be ob-
tained. Lesion refilling was performed as described
previously [22].
Longitudinal evaluation of the percentage of brain vol-
ume change (PBVC) was performed using SIENA software
only in patients not showing new T2 and/or gadolinium
enhancing lesions during follow-up. To evaluate annual-
ized PBVC (a-PBVC), the following formula was used:
PBVC/months from baseline to follow-up * 12.
Optical coherence tomography
OCT evaluations were performed using a Spectralis SD-
OCT (Heidelberg Engineering; Heidelberg, Germania).
The machine is able to record ocular movements via a
confocal scanning laser ophthalmoscope (TrueTrac ®;
Heidelberg Engineering, Heidelberg, Germany). True-
Trac have adapted the software to ocular movements,
allowing a correct examination. Eyes that were blind due
to reasons other than MS were excluded. The RNFL
examination was performed by a ring scan centred on
the optic nerve head. The follow-up study was made
using the automatic rescan mode. The thickness of glo-
bal RNFL, the temporal sector (TEMP) and the papillo-
macular bundle sector (PMB) were calculated using the
machine’s software, and an evaluation of subclinical pre-
vious optic neurotis was performed [23]. After excluding
previous clinical and subclinical ON, the minimum value
between right and left eye for the same subject was
entered for analysis. Two neurologists trained in the use
of the Spectralis SD-OCT performed all examinations.
Sample size and statistical analysis
At an alpha level of 5%, and for a statistical power of
90%, a minimum of 61 patients was needed to observe a
significant correlation of at least 0.4 (threshold between
a weak and moderate correlation).
Comparisons between MS patients and healthy controls
at baseline were made using independent samples
Student’s t-test for age, chi-square test for gender, Mann-
Whitney for education, and linear regression models for
MRI parameters and SDMT. Regression models were ad-
justed for age (MRI parameters) and education (SDMT).
Partial correlation coefficients were estimated to assess
the cross-sectional correlations at baseline between cog-
nitive functions, RNFL and MRI characteristics. These
correlations were adjusted for age, gender, EDSS (MRI
and RNFL), and education.
A multivariable model for each MRI volume (consid-
ered as dependent variable) was performed to assess
the impact, quantified by R2 value, of each RNFL and
cognitive functions characteristics on MRI parameters.
Only variables for which univariable analysis showed a
p value < 0.10 were considered for the multivariable
model, and a stepwise approach was adopted to select
those included in the model.
One-year changes in MRI, cognitive functions and
RNFL were assessed using paired samples Student’s t-test.
To assess the correlations between the longitudinal
changes in cognitive functions, RNFL and MRI charac-
teristics, partial correlation coefficients were estimated
using delta changes between baseline and one year.
Correlations between baseline and longitudinal changes
were also assessed. These were adjusted for age, gender,
EDSS (MRI and RNFL) and education.
Stata (v.14; StataCorp.) was used for the computation
of results.
Results
We included 66 MS subjects (female: 48; 72.7%) and 16
healthy controls (female: 9; 56.25%). Mean age at base-
line was 43.4 years (SD: 12) in patients, and 46.8 years
(SD: 9) in healthy controls. Mean education was 11.6 years
(SD: 4.16) in patients, and 14.3 years (SD: 4.19) in healthy
subjects. In the MS group, the mean duration of the
disease was 10.8 years and the median EDSS was 2
(range: 0 - 7.5). Ten patients were not included in
the OCT study due to poor compliance. In 4 other
patients, the OCT evaluation was made only in 1 eye,
as the other eye was blind for reasons other than MS.
Baseline values of NBV, NWV, NGV, p-NGV, SDMT,
CVLT-II, BVMT-R, average-RNFL, TEMP-RNFL, and
PMB-RNFL are reported in Table 1.
The comparison between healthy controls and patients
at baseline showed higher NBV (p = 0.006), higher NWV
(p = 0.003), and higher RNFL thickness (p = 0.014) in the
first group. The healthy subjects group also demon-
strated better performance at SDMT (p = 0.037). No
significant differences were found in NGV and p-NGV.
Cross sectional analysis in MS patients at baseline
In Table 2 were reported all baseline correlations. A signifi-
cant correlation between: p-NGV and SDMT (p = 0.022);
NGV and SDMT (p= 0.013); NGV and BVMT (p = 0.048);
TEMP-RNFL and NBV (p= 0.007); TEMP-RNFL and
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NWV (p = 0.012); TEMP-RNFL and NGV (p = 0.048);
TEMP-RNFL and p-NGV (p = 0.021); PMB-RNFL and
NBV (p = 0.013); PMB-RNFL and NWV (p = 0.02);
PMB-RNFL and NGV (p = 0.049); PMB-RNFL and p-NGV
(p = 0.032). The correlations between SDMT and p-NGV
are shown in Fig. 1, while the correlations between TEMP-
RNFL and MRI parameters in Fig. 2.
Average-RNFL thickness displayed a correlation with
both NBV (p = 0.10), and p-NGV (p = 0.06) even thought
it did not reach the statistical significance. The OCT mea-
sures did not correlate with the results of BICAMS tests.
Since p-NGV correlated with both OCT and cognitive
performances, a multivariable model was implemented.
After selection, SDMT and TEMP-RNFL, together with
age and disease duration, were significantly associated
with p-NGV (Table 3). The multivariable model in-
creased R2 from 38.3% (with age) to 48.5% with the
inclusion of SDMT (ΔR2 of 10.2%), and to 65.2% with
the inclusion of TEMP-RNFL (ΔR2 of 16.7%).
Longitudinal analysis
At follow-up, 26 patients did not repeat the OCT, 30 did
not repeat the brain MRI, and 25 did not repeat the
neuropsychological evaluation. The longitudinal evalua-
tions of all the three measures were therefore available for
36 patients, while in a further 4 subjects only OCT and
BICAMS, but not MRI, were performed at follow-up.
The mean percentage of brain volume change from base-
line to follow-up was 0.57 (SD: 0.54, p: < 0.001). All the
OCT parameters changed significantly from baseline to
follow-up. A mean decrease of 1.3 (SD: 1.7) for average-
RNFL (p < 0.001); 1.2 (SD: 1.9) for TEMP (p = 0.001); and
1.4 (SD: 2.2) for PMB (p = 0.001) was observed. No signifi-
cant changes were detected in all the BICAMS tests
results.
No significant correlation was found between OCT,
MRI and cognitive changes.
Table 1 Clinical and demographic features
MS (n = 66) HC (n = 16) p-value
Age, mean (SD) 43.4 (12) 46.8 (9) 0.32
Gender, n(%) 0.21
Females 48 (72.7) 9 (56.3)
Males 18 (27.3) 7 (43.7)
Education (years), median (range) 13 (5-21) 13 (8-19) 0.096
Disease duration, mean;
median (range)
10.8; 8.5 (0-34)
EDSS, median (range) 2 (0-7.5)
NBV, mean (SD) 1473.5 (81.9) 1519.6 (38.4) 0.006^
NWV, mean (SD) 694 (39.9) 728.1 (19.1) 0.003^
NGV, mean (SD) 777.7 (72) 791.5 (33.1) 0.14^
p-NGV, mean (SD) 609.6 (52.1) 616.2 (28.7) 0.11^
SDMT, mean (SD) 45.1 (12.3) 53.3 (8.4) 0.037*
CVLT-II, mean (SD) 41.6 (10.3) –
BVMT-R, mean (SD) 47.6 (10.8) –
RNFL, mean (SD) 93.8 (10.7) 101.8 (9.9) 0.014
TEMP-RNFL, mean (SD) 63.3 (11) –
PMB-RNFL, mean (SD) 49.6 (9.4) –
^ - linear regression model adjusted for Age; *linear regression model adjusted
for education
MRI measures (NBV, NWV, NGV, p-NGV) are expressed in ml
Cognitive measures (SDMT, CVLT-II, BVMT-R) are expressed in T score
Table 2 Partial correlations among OCT, cognitive and MRI
parameters
Neurodegenerative assessment Variables r p-value
SD-OCT
Average-RNFL SDMT 0.01 0.96
CVLT-II 0.20 0.18
BVMT-R 0.08 0.60
NBV 0.25 0.095
NWV 0.16 0.28
NGV 0.22 0.14
p-NGV 0.29 0.06
TEMP-RNFL SDMT 0.01 0.95
CVLT-II 0.09 0.57
BVMT-R 0.08 0.58
NBV 0.40 0.007
NWV 0.37 0.012
NGV 0.30 0.048
p-NGV 0.36 0.021
PMB-RNFL SDMT 0.044 0.78
CVLT-II 0.09 0.55
BVMT-R 0.13 0.38
NBV 0.37 0.013
NWV 0.35 0.02
NGV 0.30 0.049
p-NGV 0.33 0.032
SDMT NBV 0.20 0.10
NWV −0.07 0.56
NGV 0.21 0.11
p-NGV 0.31 0.022
CVLT-II NBV 0.09 0.48
NWV 0.06 0.66
NGV 0.04 0.78
p-NGV 0.01 0.97
BVMT-R NBV 0.11 0.38
NWV 0.05 0.68
NGV 0.18 0.17
p-NGV 0.22 0.11
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Discussion
We found that the evaluation of RNFL thickness by
SD-OCT and cognitive functions by BICAMS are able
to differentiate the group of MS patients from that of
healthy controls, as previously shown by numerous
studies [8–11], as well as being independent markers
of neurodegeneration. These were compared with
brain volume evaluation performed with MRI - the
most commonly used instrument for MS follow-up
and what is generally considered the gold standard
marker for monitoring the degenerative component of
the pathology.
Our data confirmed the association between both as-
sessments and brain volume measures [5, 10–14]. In
particular, we found that the BICAMS tests correlate
with NGV, especially with cortical atrophy, which is no-
toriously associated with cognitive decline [5]. Moreover,
we found a significant correlation between specific OCT
parameters (temporal quadrant and PMB thickness) and
brain volume measurements. This correlation appears to
Fig. 1 Correlation between SDMT and p-NGV
Fig. 2 Correlation between TEMP-RNFL and the following brain volume measures: NGV, NBV, NWV, and p-NGV
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be stronger with global and white brain volume than
grey matter volume. This result is in line with previous
studies in which OCT measures were found to be asso-
ciated with total brain volume and normalized white
matter volume [12, 24], or both normalized white and
grey matter volumes [11].
An innovative aspect of our work was the combined
analysis of brain atrophy, RNFL thickness, and cognitive
functions. Indeed, while the association between brain
volume and the other two parameters has been clearly
assessed previously, and confirmed by our data, there is
less evidence of a possible correlation between RNFL
thickness and cognitive impairment. Toledo et al. per-
formed a unique study exploring this issue [25]. They
found a significant correlation between SDMT and
RNFL thickness, both for the average and the temporal
quadrant. However, this result was not confirmed by our
work, and we did not observe any correlation between
RNFL (average, temporal and PMB) and BICAMS tests.
It is worth noting that Toledo et al. performed their
OCT analysis with a smaller sample and using a less ac-
curate time-domain machine.
The lack of association between RNFL thickness and
cognitive impairment, as for their correlation with differ-
ent brain volume regions (only grey matter for BICAMS
tests, both grey and white matter for TEMP-RNFL and
PMB-RNFL), leads us to hypothesize that RNFL and
cognitive impairment may represent different aspects of
neurodegeneration in MS. Indeed, cognitive decline is
secondary to axonal loss, dendritic transection and
apoptosis [26]. Moreover, as well as the grey matter
pathology, cognitive impairment is mainly associated
with primitive degeneration present from the initial
stages of the disease, as entirely independent degenera-
tive process, and only partially it is secondary to inflam-
mation. [6, 27]. Otherwise, RNFL thickness may equally
be associated with both primitive degeneration and de-
generation due to an inflammatory component. In par-
ticular, the thinning observed by OCT may be due to
clinical and subclinical episodes of ON, primary neuro-
degeneration of the retinal ganglion cells and their
axons, or retrograde transsynaptic degeneration of the
ganglion cells and their axons due to MS lesions in the
posterior visual pathways [28].
Longitudinally, no significant changes in BICAMS
tests scores emerged. This was probably due to a well-
known practice effect [20].
A reduction was observed in the mean percentage of
brain volume, and in all the OCT parameters consid-
ered. However, the longitudinal trend of the two mea-
sures did not correlate, perhaps due to the fact that they
do not reflect the same specific inflammatory and de-
generative brain damage in MS pathology. When consid-
ering the brain atrophy measure, we also need to take
into account the well-known phenomenon of so-called
‘pseudo-atrophy’ [4], which hinders the correct evalu-
ation of the degenerative and inflammatory components.
Thus, some patients could have a ‘false’ light reduction
of brain volume over the course of one year due to the
presence of inflammatory oedema. To note that all the
patients were clinically stable between baseline and
follow-up, and no active lesions in brain MRI were
observed.
The study was also subject to some limitations.
First, follow-up may have been too short to observe
significant changes in the degenerative component,
which is present since the initial stages of the disease
and is characterized by slow progression.
Second, while our cohort of participants is of a com-
parable size to that of previous cross-sectional studies, it
may be too small to provide clear longitudinal results.
Moreover, patients were heterogeneous for the duration
of disease, DMD, and grade of inflammation at MRI.
However, the great majority of them were clinically
stable during the observational period, and no optic
neuritis was recorded between baseline and follow-up.
Conclusions
Our study shows that the evaluation of brain volume,
cognitive functions, and RNFL thickness are different
continuous measures of neurodegeneration. Unconven-
tional MRI, with its significant costs and requirement
for qualified personnel, is more difficult to use in all MS
settings. BICAMS and OCT, however, which can be
performed at low cost after minimal training, may be
suitable for use in clinical practice to assess different
aspects of neurodegeneration.
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